Articles related to HEART FAILURE (HF)

HFpEF and HFmrEF collectively account for up to 75% of all heart failure cases, yet clinical research and treatment evidence in HFpEF and HFmrEF is substantially limited compared with other types of heart failure.

HF was independently associated with a 30% to 50% higher IS rate in 2007 to 2010, but this association attenuated to only 10% to 15% higher in 2015 to 2018.

Age-adjusted mortality data reveals remarkable therapeutic success in acute ischemic events while highlighting emerging challenges in chronic cardiovascular conditions requiring enhanced primary care management strategies.

Four-month mitoquinone supplementation reversed early indicators of cardiac metabolic stress in Type 2 diabetes patients, improving heart energy efficiency by 15% compared to standard treatment alone.

First randomized evidence supporting feasibility of maintaining cardiac stability with carvedilol alone after systematic withdrawal of other heart failure medications in selected patients.

FRESH-UP found no benefit in health status, hospitalizations, or mortality when restricting fluids to 1,500 mL daily in stable heart failure patients, while significantly increasing thirst distress.